Allison L Agwu1, Tzy-Jyun Yao, Susan H Eshleman, Kunjal Patel, Wei Huang, Sandra K Burchett, George K Siberry, Russell B Van Dyke. 1. From the *Division of Pediatric Infectious Diseases, Department of Pediatrics, †Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; ‡Center for Biostatistics in AIDS Research (CBAR), Harvard School of Public Health, Boston, Massachusetts; §Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland; ¶Monogram Biosciences, South San Francisco, California; ‖Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts; **Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland; and ††Section of Infectious Diseases, Department of Pediatrics, Tulane University School of Medicine, New Orleans, Los Angeles.
Abstract
BACKGROUND: Perinatally HIV-infected (PHIV) children and youth are often heavily treatment-experienced, with resultant antiretroviral resistance and limited treatment options. For those with virologic failure (VF), new agents such as CCR5 (R5) antagonists may be useful; however, reports of R5 antagonist susceptibility in children have mostly relied on genotypic testing, which may not accurately reflect the phenotypic tropism of the viral populations. We characterized phenotypic coreceptor usage among PHIV children and youth with VF on antiretroviral treatment to identify predictors of CXCR4 (X4) tropism which preclude R5 antagonist use. METHODS: Plasma samples with >1000 HIV RNA copies/mL were obtained from 73 PHIV antiretroviral treatment-treated children and youth (age 9-21 years) enrolled in the multicenter Pediatric HIV/AIDS Cohort Study. Samples were analyzed using the Trofile phenotypic assay. Multiple logistic regression was performed to identify factors associated with detectable X4 tropism. RESULTS: Tropism results were obtained for 59 (81%) of the 73 children and youth; 32 (54%) had X4-tropism. Persistent viremia (≥80% of HIV RNA measurements >400 copies/mL) was associated with detectable X4 tropism (adjusted odds ratio: 6.6, 95% confidence interval: 1.4, 31.4), while longer cumulative nucleoside reverse transcriptase inhibitor use was associated with lower risk of X4 tropism (adjusted odds ratio: 0.6, 95% confidence interval: 0.5, 0.9). CONCLUSIONS: Using a phenotypic assay, >50% of PHIV children and youth with VF had X4 tropism, similar to that in experienced adults, and higher than the 30% reported for children using genotypic assays. Persistent viremia and shorter nucleoside reverse transcriptase inhibitor exposure are associated with X4-tropism in children and youth and may help target phenotypic testing to those most likely to benefit from R5 antagonist.
BACKGROUND: Perinatally HIV-infected (PHIV) children and youth are often heavily treatment-experienced, with resultant antiretroviral resistance and limited treatment options. For those with virologic failure (VF), new agents such as CCR5 (R5) antagonists may be useful; however, reports of R5 antagonist susceptibility in children have mostly relied on genotypic testing, which may not accurately reflect the phenotypic tropism of the viral populations. We characterized phenotypic coreceptor usage among PHIV children and youth with VF on antiretroviral treatment to identify predictors of CXCR4 (X4) tropism which preclude R5 antagonist use. METHODS: Plasma samples with >1000 HIV RNA copies/mL were obtained from 73 PHIV antiretroviral treatment-treated children and youth (age 9-21 years) enrolled in the multicenter Pediatric HIV/AIDS Cohort Study. Samples were analyzed using the Trofile phenotypic assay. Multiple logistic regression was performed to identify factors associated with detectable X4 tropism. RESULTS: Tropism results were obtained for 59 (81%) of the 73 children and youth; 32 (54%) had X4-tropism. Persistent viremia (≥80% of HIV RNA measurements >400 copies/mL) was associated with detectable X4 tropism (adjusted odds ratio: 6.6, 95% confidence interval: 1.4, 31.4), while longer cumulative nucleoside reverse transcriptase inhibitor use was associated with lower risk of X4 tropism (adjusted odds ratio: 0.6, 95% confidence interval: 0.5, 0.9). CONCLUSIONS: Using a phenotypic assay, >50% of PHIV children and youth with VF had X4 tropism, similar to that in experienced adults, and higher than the 30% reported for children using genotypic assays. Persistent viremia and shorter nucleoside reverse transcriptase inhibitor exposure are associated with X4-tropism in children and youth and may help target phenotypic testing to those most likely to benefit from R5 antagonist.
Authors: Ingrid A Beck; Minyoung Jang; Jennifer McKernan-Mullin; Marta Bull; Thor Wagner; Sharon Huang; Lin-Ye Song; Sharon Nachman; Paul Krogstad; Susan H Eshleman; Andrew Wiznia; Lisa M Frenkel Journal: AIDS Res Hum Retroviruses Date: 2012-01-27 Impact factor: 2.205
Authors: L P R Vandekerckhove; A M J Wensing; R Kaiser; F Brun-Vézinet; B Clotet; A De Luca; S Dressler; F Garcia; A M Geretti; T Klimkait; K Korn; B Masquelier; C F Perno; J M Schapiro; V Soriano; A Sönnerborg; A-M Vandamme; C Verhofstede; H Walter; M Zazzi; C A B Boucher Journal: Lancet Infect Dis Date: 2011-03-21 Impact factor: 25.071
Authors: Allison L Agwu; John A Fleishman; Richard Rutstein; P Todd Korthuis; Kelly Gebo Journal: J Pediatric Infect Dis Soc Date: 2013-03-12 Impact factor: 3.164
Authors: M Koot; I P Keet; A H Vos; R E de Goede; M T Roos; R A Coutinho; F Miedema; P T Schellekens; M Tersmette Journal: Ann Intern Med Date: 1993-05-01 Impact factor: 25.391
Authors: Nametso Kelentse; Sikhulile Moyo; Mompati L Mogwele; Doreen Ditshwanelo; Baitshepi Mokaleng; Natasha O Moraka; Kwana Lechiile; Tshepo B Leeme; David S Lawrence; Rosemary Musonda; Ishmael Kasvosve; Thomas S Harrison; Joseph N Jarvis; Simani Gaseitsiwe Journal: Viruses Date: 2020-12-07 Impact factor: 5.048